>
Latest news
  - Archive
   
   
   
home | contact us | site map
News > Archive
April 2004 Oxford Optronix receives ISO 9001:2000 and ISO 13485:2003 certification
March 2003 Oxford Optronix Ltd. licenses a novel tissue oxygen monitoring technology developed by VCURES.
May 2002

Announcing ColCount™

October 2001

OxyFlo™ blood perfusion monitor receives CE-Marking
January 2001 Announcing OxyLab™ - entry-level Tissue Monitoring
 

April 2004

Oxford Optronix receives ISO 9001:2000 and ISO 13485:2003 certification.

Following a recent audit of the quality management system by AMTAC Certification Services, Oxford Optronix has received certification to ISO 9001:2000 and ISO 13485:2003. Both of these standards make use of a process based approach to quality and business management.

ISO 13485:2003, entitled Medical Devices – Quality Management Systems, is the very latest process based system for medical device manufacturers. It replaces EN 46001, which has been withdrawn. The decision to move straight to a process based system for medical devices rather than use the intermediate step of certification to ISO 13485:2001 (based upon ISO 9001:1994) was taken so that all parts of the business could immediately benefit from process based management.

In a process based system activities and related resources are linked to form a process. At Oxford Optronix we have nine processes that interact and form our business. By determining how our processes interact we are able manage them to ensure that the whole system is focused on meeting the needs of our customers. We can measure process performance and effectiveness which in turn allows us to make continual improvements to the processes and ultimately the business.

back to top


March 2003

Oxford Optronix Ltd. licenses a novel tissue oxygen monitoring technology developed by VCURES.

Oxford Optronix Ltd., a world leader in tissue oxygen and blood flow monitoring, has licensed from VCU a novel tissue oxygen monitoring technology developed by VCURES (www.vcures.org). The technology developed by VCURES uses a novel combination of spectroscopy techniques to non-invasively determine the balance of tissue oxygen delivery and utilization. The technology is envisioned to become a valuable tool in the assessment of the critically ill or injured patient for both diagnostic purposes and as a guide to treatment.

Currently, the major tools used in early assessment of severely ill or injured patients is the use of blood pressure and heart rate which are known to be notoriously deceiving and incapable of providing healthcare providers a true picture of tissue health. This new technology may have particular application in the decision making process when assessing mass casualty situations. Additionally, it may also assist doctors in developing better criteria for determining the need for blood transfusions and in assessing individual organ health during surgeries.

Oxford Optronix Ltd. CEO Dr. Andrew Obeid states “We are very excited about the opportunity to work with VCURES which has clearly established itself as an innovative leader in the study of shock and its treatment. One of the most outstanding features of this group is that they are bringing together clinicians, basic scientists and engineers to address critical and complex problems associated with acute illness and injury”.

Oxford Optronix Ltd. and VCURES will work aggressively to develop a clinical prototype for testing in the near future. For more information, please contact Oxford Optronix Ltd or VCURES.

back to top


May 2002

Announcing ColCount™

An automated counter of mammalian cell colonies ColCount™ is a fully automated, laboratory bench-top system developed specifically for counting mammalian cell colonies resulting from the clonogenic cell-survival assay.

ColCount™ will be of particular interest to Cell and Radiation Biologists looking for a powerful, versatile and cost-effective alternative to labour-intensive manual counting methods.

back to top


October 2001

OxyFlo™ blood perfusion monitor receives CE-Marking

Introducing 'OxyFlo C', where 'C' stands for 'Clinical'.

Oxford Optronix proudly announces that our proven and popular multi-channel blood perfusion monitor is now CE-marked for clinical use in Europe.

Ground-breaking features of the new OxyFlo C™ include the introduction of a unique range of re-usable needle and tissue surface sensors that can be sterilized up to 20 times using standard hospital autoclave sterilizers. For the user this means improved patient safety, ease-of-use and value for money.

back to top


January 2001

Announcing OxyLab™ - entry-level Tissue Monitoring

Oxford Optronix proudly presents OxyLab™, an entry-level, single channel Tissue Monitoring System specifically developed for the laboratory and experimental user.

OxyLab™ is based on the established, award winning, fibre-optic technology of our professional, multi-channel OxyLite™ systems.

back to top


 

 

 

 

Corporate  
Shows  
  Products